Y0000429

Trospium chloride

Name: Trospium chloride
Brand: SIAL
Price: 254 USD
Availability: InStock

European Pharmacopoeia (EP) Reference Standard

Slide 1 of 1

Select a Size

15 MG

$254.00

Estimated to ship onJanuary 20, 2026Details

Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):

C₂₅H₃₀ClNO₃

CAS Number:

10405-02-4

Molecular Weight:

427.96

UNSPSC Code:

41116107

NACRES:

NA.24

Key Documents

View All Documentation

Product Name

Trospium chloride, European Pharmacopoeia (EP) Reference Standard

SMILES string

[Cl-].[N+]21(C3CCC2CC(C3)OC(=O)C(O)(c5ccccc5)c4ccccc4)CCCC1

InChI

1S/C25H30NO3.ClH/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26;/h1-6,9-12,21-23,28H,7-8,13-18H2;1H/q+1;/p-1

InChI key

RVCSYOQWLPPAOA-UHFFFAOYSA-M

grade

pharmaceutical primary standard

API family

trospium

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Materials for Pharma QC

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item	1699300	BP1064	PHR3378
Y0000429 Trospium chloride	USP 1699300 Trospium chloride	BP1064 Trospium chloride	Supelco PHR3378 Trospium chloride
grade pharmaceutical primary standard	grade pharmaceutical primary standard	grade pharmaceutical primary standard	grade certified reference material, pharmaceutical secondary standard
manufacturer/tradename EDQM	manufacturer/tradename USP	manufacturer/tradename BP	manufacturer/tradename -
application(s) pharmaceutical (small molecule)	application(s) pharmaceutical (small molecule)	application(s) pharmaceutical pharmaceutical small molecule	application(s) pharmaceutical small molecule
format neat	format neat	format neat	format -
API family trospium	API family trospium	API family trospium	API family -
storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-30°C

Application

Trospium chloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

[Clinical and urodynamic rationale of the overactive bladder neurophysiological model].

V V Danilov et al.

Urologiia (Moscow, Russia : 1999), (4)(4), 15-20 (2010-10-26)

The analysis of 58 cases of overactive bladder has shown that detrusor activity is not linked with clinical symptoms but is caused by supra segmentary lesion of the nervous system. The clinical picture of overactive bladder fits the proposed neurophysiological

Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder.

Scott A MacDiarmid et al.

Urology, 77(1), 24-29 (2010-10-26)

This study used pooled data from 2 large, phase III, double-blind, randomized, placebo-controlled studies for a subgroup analysis of the safety and efficacy of trospium chloride extended-release (XR) in men with overactive bladder (OAB). A subgroup analysis was performed on

Characterizing crystal disorder of trospium chloride: a comprehensive,(13) C CP/MAS NMR, DSC, FTIR, and XRPD study.

Martina Urbanova et al.

Journal of pharmaceutical sciences, 102(4), 1235-1248 (2013-01-30)

Analysis of C cross-polarization magic angle spinning (CP/MAS) nuclear magnetic resonance (NMR), differential scanning calorimetry (DSC), Fourier transform infrared (FTIR), and X-ray powder diffraction data of trospium chloride (TCl) products crystallized from different mixtures of water-ethanol [φ(EtOH) = 0.5-1.0] at

Pharmacokinetic and bioequivalence studies of trospium chloride after a single-dose administration in healthy Chinese volunteers.

R Zhang et al.

Arzneimittel-Forschung, 62(5), 247-251 (2012-03-03)

The study aimed to compare and evaluate the bioequivalence of a new generic preparation of trospium chloride (CAS NO:10405-02-4) capsule (20 mg, test) and the available import tablet (20 mg , reference) for the requirement of state regulatory criteria in

Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.

Anthony G Visco et al.

The New England journal of medicine, 367(19), 1803-1813 (2012-10-06)

Anticholinergic medications and onabotulinumtoxinA are used to treat urgency urinary incontinence, but data directly comparing the two types of therapy are needed. We performed a double-blind, double-placebo-controlled, randomized trial involving women with idiopathic urgency urinary incontinence who had five or

View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service